Published in Diabetes Care on August 22, 2014
Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovasc Diabetol (2015) 0.84
Modulating DDAH/NOS Pathway to Discover Vasoprotective Insulin Sensitizers. J Diabetes Res (2015) 0.81
Antidiabetic and cardiovascular drug utilisation in patients diagnosed with type 2 diabetes mellitus over the age of 80 years: a population-based cohort study. Age Ageing (2015) 0.78
Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure. Am J Transl Res (2016) 0.75
Controversy about the relationship between sulfonylurea use and cardiovascular events and mortality. J Diabetes Investig (2016) 0.75
Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence. Trends Endocrinol Metab (2017) 0.75
Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease. Diabetes (2017) 0.75
10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med (2008) 35.49
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 34.34
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
Severe hypoglycemia and risks of vascular events and death. N Engl J Med (2010) 8.54
Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet (1991) 7.87
Alternative dietary indices both strongly predict risk of chronic disease. J Nutr (2012) 5.60
Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation (2007) 4.97
Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf (2006) 4.64
A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes (1970) 4.57
Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care (1998) 4.49
Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia (2006) 3.94
Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care (1998) 3.34
Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med (1987) 2.98
Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J (2005) 2.71
Ophthalmic examination among adults with diagnosed diabetes mellitus. JAMA (1993) 2.52
The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies. Stat Med (2010) 2.39
Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med (2012) 2.18
Symptoms of sensory neuropathy in adults with NIDDM in the U.S. population. Diabetes Care (1993) 2.06
Age at natural menopause and risk of cardiovascular disease. Arch Intern Med (1999) 1.90
Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ (2006) 1.80
Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab (2013) 1.71
Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf (2007) 1.25
Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med (2013) 1.23
Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia (2000) 1.02
Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes (2002) 0.99
Haemoglobin A1c levels and subsequent cardiovascular disease in persons without diabetes: a meta-analysis of prospective cohorts. Diabetologia (2011) 0.96
Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther (2010) 0.95
Bounding the bias of unmeasured factors with confounding and effect-modifying potentials. Stat Med (2011) 0.95
Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst Rev (2013) 0.93
Initiation of sulfonylureas versus metformin is associated with higher blood pressure at one year. Pharmacoepidemiol Drug Saf (2012) 0.92
Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol (2001) 0.86
Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy. Eur J Clin Pharmacol (2010) 0.84
Metformin and risk of cardiovascular disease. Cardiology (1999) 0.78
All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes Metab Res Rev (2004) 0.77
John EVANS (1814-1897). His contributions to medicine and other fields. JAMA (1961) 0.77
Restless legs syndrome: an early clinical feature of Parkinson disease in men. Sleep (2014) 0.87
Genetic Predisposition to Central Obesity and Risk of Type 2 Diabetes: Two Independent Cohort Studies. Diabetes Care (2015) 0.81